Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will become the first approved treatment for cardiomyopathy associated with ...

The FDA has launched a formal investigation into two reports of fatal acute liver failure in patients treated with Sarepta and Roche's Duchenne muscular dystrophy (DMD) gene therapy Elevidys. The two ...

Vamos a decirte los cinco lenguajes de programación más populares del momento, que son posiblemente los que más salida tengan en este 2026. Además de esto, también te daremos una pequeña colección de ...

Recientemente Qualcomm, empresa que fabrica los procesadores que llevan muchos de los móviles, tabletas y otros dispositivos que usamos habitualmente, anunció en un evento internacional en Turín el ...

With over 8.9 million micromirrors, TI’s DLP991UUV digital micromirror device (DMD) enables maskless digital lithography for advanced packaging. Its 4096×2176 micromirror array, 5.4-µm pitch, and ...

Duchenne muscular dystrophy (DMD) causes muscle weakness that becomes more severe over time. While there is no cure, treatments can help slow the progression and manage symptoms and complications.

Capricor Therapeutics is advancing deramiocel (CAP-1002) for DMD cardiomyopathy, with a BLA resubmission and HOPE-3 topline data expected by 2026. CAPR's therapy addresses a critical unmet need in non ...

Duchenne muscular dystrophy (DMD) occurs as a result of genetic changes on the X chromosome. If someone has a gene change that can cause DMD, their children may inherit that change. DMD is a ...

We have moved NG251 to become a 'NICE Review'. This is to better reflect what the purpose of this product is and to help you find relevant content more quickly. The review itself has not changed. See ...

After an unconventional public display of disapproval, the FDA has made a stunning reversal on Sarepta Therapeutics’ Elevidys, recommending that Duchenne muscular dystrophy (DMD) patients who can walk ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...

A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile. Sarepta and its ex-U.S ...